How many CROs should you invite to bid? For most emerging biotech studies, fewer than you think. A right-sized bid list of CROs that can genuinely win on fit produces stronger proposals, more senior attention and a clearer decision than a long list assembled to feel thorough. In the ABRA PROOF™ Method, this is the second stage, Right-size the Field: we invite only the CROs that can genuinely win on fit, not on reputation alone.
Long bid lists are usually a symptom of uncertainty. When a sponsor is not sure what it needs, inviting many CROs feels like a way to keep options open. In practice it creates more work for your team, weaker proposals from bidders and a comparison that is harder to complete well.
Why do long CRO bid lists backfire?
CROs make bid decisions too. Proposal teams are finite, and they prioritize opportunities they believe they can win. When a CRO sees a crowded field, your opportunity may go to a junior proposal team, be priced defensively or be answered with standard language rather than study-specific thinking. You get the proposal they can afford to write, not the one your study deserves.
Your team pays a cost too. Every additional bidder means more clarification questions, more documents to review, more bid defense meetings and more reference calls. Lean sponsor teams rarely have that capacity, so evaluation quality drops as the list grows.
Finally, a long list hides weak fits. A CRO that was never well suited to your study can still produce a polished response. If it advances because the field is too large to scrutinize, it consumes attention that belonged to the real contenders.
What makes a CRO a genuine fit to invite?
Fit is specific to the program. Questions worth asking before you invite anyone include:
Has this CRO recently run studies like yours, at a similar phase, size and complexity?
Is a study of your size meaningful to this organization, or likely to be one of hundreds?
Does it have real operating presence in the countries and site networks you need?
Can it deliver the services you plan to outsource without stitching together subcontractors you have not assessed?
Is there evidence of the senior attention and continuity your program requires?
A CRO that cannot answer these convincingly before the RFP is unlikely to answer them convincingly afterward.
Is it risky to invite only a few CROs?
Some sponsors worry that a short list reduces competitive pressure on price. In my experience the opposite tends to happen. When bidders know they are one of a small number of serious contenders, they invest more in understanding the study, field stronger proposal teams and engage more openly in negotiation. Competition is about the quality of the field, not its size.
The real risk is a list that is short for the wrong reasons: only the names your board recognizes, only the CROs that called first, or the incumbent plus one comparator invited to validate a decision already made. Right-sizing is a deliberate exercise grounded in fit, not familiarity.
What sponsors gain from Right-size the Field
Fit is one of the four factors I see derail CRO selections most often, alongside team continuity, budget comparability and open assumptions. When the field is right-sized, every CRO in the process has a credible path to winning your work, and it behaves accordingly. Your team can evaluate each proposal thoroughly, and bid defenses become substantive conversations rather than marathon presentations. You finish the stage with a shortlist that has a clear reason for every cut, signed off before the bid begins.
Right-sizing also protects your relationships with the CROs you do not select. A bidder that was invited for good reason and treated fairly is far more likely to welcome your next opportunity.
For a deeper look at fit, read Not All CROs Are Built for All Programs.
